Cargando…
Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
Atypical antipsychotic drugs are commonly associated with undesirable side effects including body weight gain (BWG) and metabolic deficits. Many pharmacological interventions have been tested in an attempt to minimize or prevent these side effects. Preliminary evidence suggests that antidiabetic dru...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089480/ https://www.ncbi.nlm.nih.gov/pubmed/33953666 http://dx.doi.org/10.3389/fphar.2021.578716 |
_version_ | 1783687048210677760 |
---|---|
author | Ashraf, Ghulam Md Alghamdi, Badrah S. Alshehri, Fahad S. Alam, Mohammad Zubair Tayeb, Haythum O. Tarazi, Frank I. |
author_facet | Ashraf, Ghulam Md Alghamdi, Badrah S. Alshehri, Fahad S. Alam, Mohammad Zubair Tayeb, Haythum O. Tarazi, Frank I. |
author_sort | Ashraf, Ghulam Md |
collection | PubMed |
description | Atypical antipsychotic drugs are commonly associated with undesirable side effects including body weight gain (BWG) and metabolic deficits. Many pharmacological interventions have been tested in an attempt to minimize or prevent these side effects. Preliminary evidence suggests that antidiabetic drugs may be effective in attenuating antipsychotic-induced BWG. In the current study, we examined the effect of an antidiabetic drug empagliflozin (EMPA) on BWG induced by anatypical antipsychotic drug olanzapine (Ola) in female and male Wistar rats. Rats were divided into six groups based on the dose they received: group 1 (female control), group 2 (female EMPA, 20 mg/kg; IG), group 3 (female Ola, 4 mg/kg; IP), group 4 (female Ola, 4 mg/kg; IP + EMPA, 20 mg/kg; IG), group 5 (male control), and group 6 (male Ola, 4 mg/kg; IP). Ola induced sustained increase in BWG. The subsequent treatment of Group 3 and 4 with EMPA attenuated the Ola-induced BWG in female Wistar rats. In terms of the gender difference between female and male Wistar rats, the male control group 5 gained more weight throughout the study as compared to the female control group 1. Similarly, the male Ola group 6 gained more weight throughout the study as compared to the female Ola group 3. However, Ola did not cause any weight difference between male rats treated with Ola in comparison with male control group, thus showing a significant gender difference regarding body weight between male and female Wistar rats regardless of Ola administration. In addition, the present findings showed that EMPA effectively attenuates the Ola induced BWG in female Wistar rats. These novel findings should help to better understand the underlying molecular and behavioral mechanisms contributing to the observed increase in body weight after treatment with Ola and other atypical antipsychotic drugs across male and female rats. |
format | Online Article Text |
id | pubmed-8089480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80894802021-05-04 Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats Ashraf, Ghulam Md Alghamdi, Badrah S. Alshehri, Fahad S. Alam, Mohammad Zubair Tayeb, Haythum O. Tarazi, Frank I. Front Pharmacol Pharmacology Atypical antipsychotic drugs are commonly associated with undesirable side effects including body weight gain (BWG) and metabolic deficits. Many pharmacological interventions have been tested in an attempt to minimize or prevent these side effects. Preliminary evidence suggests that antidiabetic drugs may be effective in attenuating antipsychotic-induced BWG. In the current study, we examined the effect of an antidiabetic drug empagliflozin (EMPA) on BWG induced by anatypical antipsychotic drug olanzapine (Ola) in female and male Wistar rats. Rats were divided into six groups based on the dose they received: group 1 (female control), group 2 (female EMPA, 20 mg/kg; IG), group 3 (female Ola, 4 mg/kg; IP), group 4 (female Ola, 4 mg/kg; IP + EMPA, 20 mg/kg; IG), group 5 (male control), and group 6 (male Ola, 4 mg/kg; IP). Ola induced sustained increase in BWG. The subsequent treatment of Group 3 and 4 with EMPA attenuated the Ola-induced BWG in female Wistar rats. In terms of the gender difference between female and male Wistar rats, the male control group 5 gained more weight throughout the study as compared to the female control group 1. Similarly, the male Ola group 6 gained more weight throughout the study as compared to the female Ola group 3. However, Ola did not cause any weight difference between male rats treated with Ola in comparison with male control group, thus showing a significant gender difference regarding body weight between male and female Wistar rats regardless of Ola administration. In addition, the present findings showed that EMPA effectively attenuates the Ola induced BWG in female Wistar rats. These novel findings should help to better understand the underlying molecular and behavioral mechanisms contributing to the observed increase in body weight after treatment with Ola and other atypical antipsychotic drugs across male and female rats. Frontiers Media S.A. 2021-04-19 /pmc/articles/PMC8089480/ /pubmed/33953666 http://dx.doi.org/10.3389/fphar.2021.578716 Text en Copyright © 2021 Ashraf, Alghamdi, Alshehri, Alam, Tayeb and Tarazi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ashraf, Ghulam Md Alghamdi, Badrah S. Alshehri, Fahad S. Alam, Mohammad Zubair Tayeb, Haythum O. Tarazi, Frank I. Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats |
title | Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats |
title_full | Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats |
title_fullStr | Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats |
title_full_unstemmed | Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats |
title_short | Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats |
title_sort | empagliflozin effectively attenuates olanzapine-induced body weight gain in female wistar rats |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089480/ https://www.ncbi.nlm.nih.gov/pubmed/33953666 http://dx.doi.org/10.3389/fphar.2021.578716 |
work_keys_str_mv | AT ashrafghulammd empagliflozineffectivelyattenuatesolanzapineinducedbodyweightgaininfemalewistarrats AT alghamdibadrahs empagliflozineffectivelyattenuatesolanzapineinducedbodyweightgaininfemalewistarrats AT alshehrifahads empagliflozineffectivelyattenuatesolanzapineinducedbodyweightgaininfemalewistarrats AT alammohammadzubair empagliflozineffectivelyattenuatesolanzapineinducedbodyweightgaininfemalewistarrats AT tayebhaythumo empagliflozineffectivelyattenuatesolanzapineinducedbodyweightgaininfemalewistarrats AT tarazifranki empagliflozineffectivelyattenuatesolanzapineinducedbodyweightgaininfemalewistarrats |